Weill Medical College of Cornell University
New York, 10021, United States
NCT Number: NCT03991936
This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
New York, 10021, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Normal saline intralesional injection
Other names: Saline solution for injection
2.5 mg/mL intralesional injection
Other names: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
5.0 mg/mL intralesional injection
Other names: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
7.5 mg/mL intralesional injection
Other names: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
10 mg/mL intralesional injection
Other names: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
Time frame: 24 weeks (end of study)
The most effective concentration of intralesional triamcinolone acetonide will be determined between 0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 7.5 mg/mL, and 10.0 mg/mL.
Time frame: Baseline, 24 weeks (end of study)
The Nail Psoriasis Severity Index (NAPSI) is used to evaluate nail psoriasis. Scores range from 0 to 8 with 0 indicating no nail psoriasis and higher scores indicating worsening nail psoriasis.
Time frame: Baseline, 24 weeks (end of study)
The NPQ10 comprises 10 questions gauging the impact of nail psoriasis on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, reflecting the proportion of questions answered by the patient. The obtained score correlates proportionally with the level of functional difficulty experienced, with 0% indicating no impairment and 100% indicating the worst possible impairment.
Time frame: 24 weeks (end of study)
Adverse events will only include those that are determined to be related to the study drug.
Weill Medical College of Cornell University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04580537
Nail Diseases, Nail Psoriasis
Copenhagen, Capital Region, Denmark
View Trial DetailsNCT05124080
Nail Psoriasis
Birmingham, Alabama, United States
View Trial DetailsNCT04227288
Nail Psoriasis
Birmingham, Alabama, United States
View Trial DetailsNCT04380597
Nail Psoriasis
Pontevedra, Spain
View Trial Details